Sixteen trials (29,008 participants) were included.
Average reductions in total and low-density lipoprotein cholesterol were 22 and 30%, respectively.
Reductions in risks of stroke: 29% (95% confidence interval, CI: 14, 41).
Reductions in deaths due to CVD: 28% (95% CI: 16, 37).
Reduction in total mortality: 22% (95% CI: 12, 31).
Non-CVD mortality unchanged: relative risk 0.93 (95% CI: 0.75, 1.14).
Cancer risk unchanged: relative risk 1.03 (95% CI: 0.90, 1.17).